AlokSahayMD

Neurology • Hamilton, OH

Movement Disorder

Professor, Neurology & Rehabilitation, University of Cincinnati College of Medicine

Join to view full profile

Dr. Sahay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sahay's full profile

Already have an account?

Office
7690 Discovery Dr
Hamilton, OH 45069
Phone+1 513-475-8730

Fax+1 513-475-8273
Is this information wrong?

Education & Training

Oregon Health Science University HospitalFellowship, Movement Disoders, 2000 - 2001
University of Cincinnati Medical Center/College of MedicineResidency, Neurology, 1997 - 2000
Sawai Man Singh Medical CollegeMD, Medicine, 1985 - 1988
Sawai Man Singh Medical CollegeClass of 1984, M.B.,B.S.

Certifications & Licensure

OR State Medical License 2000 - Present
OH State Medical License 1999 - 2026
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease Start of enrollment: 2002 Mar 01
Terminated
Phase 2, Phase 3
Parkinson's Research: The Organized Genetics Initiative Start of enrollment: 1998 Aug 01
Completed
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease Start of enrollment: 2005 Nov 01
Completed
Phase 3
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia Start of enrollment: 2002 Jul 01
Completed
Phase 2
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's Start of enrollment: 2003 Dec 01
Completed
Phase 3
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients Start of enrollment: 2006 Nov 01
Completed
Phase 4
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease Start of enrollment: 2008 Dec 01
Terminated
Phase 3
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease Start of enrollment: 2009 Jul 01
Completed
Phase 2
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Start of enrollment: 2009 Jul 01
Completed
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease Start of enrollment: 2009 Dec 01
Completed
Phase 4
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD) Start of enrollment: 2010 Nov 01
Completed
Phase 2
Efficacy of Isradipine in Early Parkinson Disease Start of enrollment: 2014 Nov 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study: Effects on Nonmotor Symptoms and Tolerability.
Smith KM Eyal E Weintraub D> ;JAMA Neurol. 2015 Jan 1
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.
Nalls MA Pankratz N Lill CM Do CB Hernandez DG Saad M DeStefano AL Kara E Bras J Sharma M Schulte C Keller MF Arepalli S Letson C Edsall C Stefansson H ...> ;Nat Genet. 2014 Sep
Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Hauser RA Silver D Choudhry A Eyal E Isaacson S> ;Mov Disord. 2014 Jul
Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.
Marek K Seibyl J Eberly S Oakes D Shoulson I Lang AE Hyson C Jennings D> ;Neurology. 2014 May 20
233 citations
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit
M. Flint Beal, David Oakes, Ira Shoulson, Claire Henchcliffe, Wendy R. Galpern, Richard H. Haas, Jorge L. Juncos, John G. Nutt, Tiffini Voss, Bernard Ravina, Clifford ...> ;JAMA Neurology. 2014 May 1
Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.
Stocchi F> ;Eur J Neurol. 2014 Feb
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin((R))) in cervical dystonia.
Evidente VG Fernandez HH LeDoux MS Brashear A Grafe S Hanschmann A Comella CL> ;J Neural Transm. 2013 Dec
Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
> ;Mov Disord. 2013 Nov
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin((R))) injections in blepharospasm.
Truong DD Gollomp SM Jankovic J LeWitt PA Marx M Hanschmann A Fernandez HH> ;J Neural Transm. 2013 Sep
Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naive Subjects with Cervical Dystonia.
Fernandez HH Pappert EJ Comella CL Evidente VG Truong DD Verma A Jankovic J> ;Tremor Other Hyperkinet Mov (N Y). 2013
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2.
Pankratz N Beecham GW DeStefano AL Dawson TM Doheny KF Factor SA Hamza TH Hung AY Hyman BT Ivinson AJ Krainc D Latourelle JC Clark LN Marder K Martin ER ...> ;Ann Neurol. 2012 Mar
Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".
Schwarzschild MA Marek K Eberly S Oakes D Shoulson I Jennings D Seibyl J Ascherio A> ;Mov Disord. 2011 Aug 15
104 citations
Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease
Alberto J. Espay, Joseph P. Giuffrida, Robert Chen, Megan Payne, Filomena Mazzella, Emily Dunn, Jennifer E. Vaughan, Andrew P. Duker, Alok Sahay, Sang Jin Kim, Fredy J...> ;Movement Disorders. 2011 Dec 1
125 citations
The Modified Bradykinesia Rating Scale for Parkinson’s Disease: Reliability and Comparison with Kinematic Measures
Dustin A. Heldman, Joseph P. Giuffrida, Robert Chen, Megan Payne, Filomena Mazzella, Andrew P. Duker, Alok Sahay, Sang Jin Kim, Fredy J. Revilla, Alberto J. Espay> ;Movement Disorders. 2011 Aug 15
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.
Comella CL Jankovic J Truong DD Hanschmann A Grafe S> ;J Neurol Sci. 2011 Sep 15
Copy number variation in familial Parkinson disease.
Pankratz N Dumitriu A Hetrick KN Sun M Latourelle JC Wilk JB Halter C Doheny KF Gusella JF Nichols WC Myers RH Foroud T DeStefano AL> ;PLoS One. 2011
Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.
Marras C McDermott MP Marek K Rochon P Naglie G Tanner CM Rudolph A Shoulson I Lang AE> ;Mov Disord. 2011 Mar
3 citations
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.
A J Espay, A K Dwivedi, M Payne, L Gaines, J E Vaughan, B N Maddux, J T Slevin, M Gartner, A Sahay, F J Revilla, A P Duker, R Shukla> ;Neurology. 2011 Apr 5
9 citations
Botulinum toxin type A for Levodopa‐induced cervical dyskinesias in Parkinson's disease: Unfavorable risk‐benefit ratio
Alberto J. Espay, Jennifer E. Vaughan, Rakesh Shukla, Maureen Gartner, Alok Sahay, Fredy J. Revilla, Andrew P. Duker> ;Movement Disorders. 2011 Apr 1
Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
Kieburtz K> ;Mov Disord. 2011 Jan
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
Schwid SR Bausch J Oakes D Schuchter L Tanner C Forrest M Lang AE Shoulson I Shoulson I Hyson C Oakes D Flagg E Rudolph A Kieburtz K Lang A Fahn S Gaug...> ;Mov Disord. 2010 Sep 15
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL Lyons KE Pahwa R Sethi K Stern M Hauser RA Olanow W Gray AM Adams B Earl NL> ;Mov Disord. 2010 May 15
Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease.
Simon DK Pankratz N Kissell DK Pauciulo MW Halter CA Rudolph A Pfeiffer RF Nichols WC Foroud T> ;BMC Med Genet. 2010
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Marras C Lang AE Eberly SW Oakes D Fahn S Schwid SR Hyson C Shoulson I> ;Mov Disord. 2009 Dec 15
Genomewide association study for onset age in Parkinson disease.
Latourelle JC Pankratz N Dumitriu A Wilk JB Goldwurm S Pezzoli G Mariani CB DeStefano AL Halter C Gusella JF Nichols WC Myers RH Foroud T> ;BMC Med Genet. 2009
Join now to see all

Professional Memberships

American Academy of Neurology - AAN
Member
American Medical Association - AMA
Member
Movement Disorder Society
Member
Parkinson Study Group
Member
International Parkinson and Movement Disorder Society - MDS
Member

Other Languages

Hindi

Hospital Affiliations

University of Cincinnati Medical CenterCincinnati, Ohio
Cincinnati Veterans Affairs Medical CenterCincinnati, Ohio